标题
Mitochondrial metabolism promotes adaptation to proteotoxic stress
作者
关键词
-
出版物
Nature Chemical Biology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-28
DOI
10.1038/s41589-019-0291-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- ISCU(M108I) and ISCU(D39V) Differ from Wild-Type ISCU in Their Failure To Form Cysteine Desulfurase Complexes Containing Both Frataxin and Ferredoxin
- (2018) Kai Cai et al. BIOCHEMISTRY
- Interactions of iron-bound frataxin with ISCU and ferredoxin on the cysteine desulfurase complex leading to Fe-S cluster assembly
- (2018) Kai Cai et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Elesclomol restores mitochondrial function in genetic models of copper deficiency
- (2018) Shivatheja Soma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
- (2017) Chang-Xin Shi et al. MOLECULAR CANCER THERAPEUTICS
- Gene Architectures that Minimize Cost of Gene Expression
- (2017) Idan Frumkin et al. MOLECULAR CELL
- Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
- (2017) Elodie M Kuntz et al. NATURE MEDICINE
- Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling
- (2016) Xing-Ding Zhang et al. CANCER CELL
- Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer
- (2016) D S Matassa et al. CELL DEATH AND DIFFERENTIATION
- A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation
- (2016) Jason D. Arroyo et al. Cell Metabolism
- Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
- (2016) G P Soriano et al. LEUKEMIA
- Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways
- (2016) Rachel Raynes et al. MOLECULAR ASPECTS OF MEDICINE
- An evolutionarily conserved pathway controls proteasome homeostasis
- (2016) Adrien Rousseau et al. NATURE
- High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines
- (2016) Channing Yu et al. NATURE BIOTECHNOLOGY
- Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
- (2016) Peter Tsvetkov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SIRT1/PGC1 -Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer
- (2015) T. T. Vellinga et al. CLINICAL CANCER RESEARCH
- The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
- (2015) Bingzong Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
- (2015) Jinghui Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
- (2015) Peter Tsvetkov et al. eLife
- Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
- (2015) Diego Acosta-Alvear et al. eLife
- Dose-Response Analysis Using R
- (2015) Christian Ritz et al. PLoS One
- Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
- (2014) Raymond J Deshaies BMC BIOLOGY
- Regulation of Ferroptotic Cancer Cell Death by GPX4
- (2014) Wan Seok Yang et al. CELL
- NADH Binds and Stabilizes the 26S Proteasomes Independent of ATP
- (2014) Peter Tsvetkov et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)
- (2014) Brian B. Hasinoff et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Structure–Activity Relationships for Withanolides as Inducers of the Cellular Heat-Shock Response
- (2014) E. M. Kithsiri Wijeratne et al. JOURNAL OF MEDICINAL CHEMISTRY
- TCGA-Assembler: open-source software for retrieving and processing TCGA data
- (2014) Yitan Zhu et al. NATURE METHODS
- A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
- (2013) Fabio Petrocca et al. CANCER CELL
- PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress
- (2013) Francisca Vazquez et al. CANCER CELL
- Proteasome Regulation by ADP-Ribosylation
- (2013) Park F. Cho-Park et al. CELL
- The ATP Costs and Time Required to Degrade Ubiquitinated Proteins by the 26 S Proteasome
- (2013) Andreas Peth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)
- (2013) Arun A. Yadav et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
- (2012) Masazumi Nagai et al. FREE RADICAL BIOLOGY AND MEDICINE
- Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
- (2012) Amila Suraweera et al. MOLECULAR CELL
- Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol
- (2012) Ronald K. Blackman et al. PLoS One
- Mitochondrial Respiration - An Important Therapeutic Target in Melanoma
- (2012) Michelle Barbi de Moura et al. PLoS One
- Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis
- (2011) Yanbo Shi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Copper Binding Agents Acting as Copper Ionophores Lead to Caspase Inhibition and Paraptotic Cell Death in Human Cancer Cells
- (2011) Saverio Tardito et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines
- (2010) S. L. Holbeck et al. MOLECULAR CANCER THERAPEUTICS
- Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis
- (2010) Vishal M Gohil et al. NATURE BIOTECHNOLOGY
- Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis
- (2010) A. D. Sheftel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
- (2009) Steven O'Day et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
- (2008) R. Z. Orlowski et al. CLINICAL CANCER RESEARCH
- Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells
- (2008) S. Markovina et al. MOLECULAR CANCER RESEARCH
- Elesclomol induces cancer cell apoptosis through oxidative stress
- (2008) J. R. Kirshner et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More